Actively Recruiting
Global Phase 2b Randomized Trial of Ninerafaxstat Versus Placebo in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Led by Imbria Pharmaceuticals, Inc. · Updated on 2026-10-26
165
Participants Needed
76
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy nHCM. This global, multicenter, double-blind, placebo-controlled Phase 2b study aims to assess the efficacy and safety of ninerafaxstat compared to placebo when added to standard care for this condition. Participants will receive either ninerafaxstat 200mg modified release tablets or matching placebo tablets, both administered twice daily. The study uses a randomized parallel-group design to compare these treatments over a 12-week period, focusing on changes in patient symptoms and functional status. Throughout the study, participants will undergo cardiopulmonary exercise testing and complete the Kansas City Cardiomyopathy Questionnaire to measure changes in clinical symptoms and physical limitations. The primary outcome is the change in the questionnaires Clinical Summary Score from baseline to week 12. Safety and secondary outcomes related to exercise efficiency and symptom scores will also be monitored. The study is expected to conclude in December 2026.
CONDITIONS
Brief Title
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Research Team
M
Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here